JP7114490B2 - キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 - Google Patents

キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 Download PDF

Info

Publication number
JP7114490B2
JP7114490B2 JP2018567062A JP2018567062A JP7114490B2 JP 7114490 B2 JP7114490 B2 JP 7114490B2 JP 2018567062 A JP2018567062 A JP 2018567062A JP 2018567062 A JP2018567062 A JP 2018567062A JP 7114490 B2 JP7114490 B2 JP 7114490B2
Authority
JP
Japan
Prior art keywords
cells
car
cell
target
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018567062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522973A5 (enExample
JP2019522973A (ja
Inventor
ユポ・マ
ケヴィン・ピンズ
シュン・ジャン
マサユキ・ワダ
ケヴィン・チェン
Original Assignee
アイセル・ジーン・セラピューティクス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/039306 external-priority patent/WO2016210293A1/en
Application filed by アイセル・ジーン・セラピューティクス・エルエルシー filed Critical アイセル・ジーン・セラピューティクス・エルエルシー
Publication of JP2019522973A publication Critical patent/JP2019522973A/ja
Publication of JP2019522973A5 publication Critical patent/JP2019522973A5/ja
Application granted granted Critical
Publication of JP7114490B2 publication Critical patent/JP7114490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018567062A 2016-06-24 2016-12-22 キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 Active JP7114490B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
USPCT/US2016/039306 2016-06-24
PCT/US2016/039306 WO2016210293A1 (en) 2015-06-25 2016-06-24 CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
US201662369004P 2016-07-29 2016-07-29
US62/369,004 2016-07-29
PCT/US2016/068349 WO2017222593A1 (en) 2016-06-24 2016-12-22 Chimeric antigen receptors (cars), compositions and methods thereof

Publications (3)

Publication Number Publication Date
JP2019522973A JP2019522973A (ja) 2019-08-22
JP2019522973A5 JP2019522973A5 (enExample) 2020-02-06
JP7114490B2 true JP7114490B2 (ja) 2022-08-08

Family

ID=60783276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018567062A Active JP7114490B2 (ja) 2016-06-24 2016-12-22 キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法

Country Status (6)

Country Link
US (4) US20200283534A1 (enExample)
EP (2) EP3474867A4 (enExample)
JP (1) JP7114490B2 (enExample)
CN (1) CN109562126A (enExample)
CA (1) CA3029197A1 (enExample)
WO (1) WO2017222593A1 (enExample)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015357535B2 (en) 2014-12-05 2020-05-14 Eureka Therapeutics, Inc. Antibodies targeting G-protein coupled receptor and methods of use
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
HRP20220890T1 (hr) 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
US20220348633A1 (en) * 2015-06-25 2022-11-03 Icell Gene Therapeutics Llc COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
US20220241327A1 (en) * 2015-06-25 2022-08-04 Icell Gene Therapeutics Llc Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof
EP3368571B1 (en) 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
MA43134A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes de transduction tumorale
US11384156B2 (en) * 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
CA3039136A1 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
CA3042613A1 (en) * 2016-11-11 2018-05-17 Autolus Limited Chimeric antigen receptor
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3568406A4 (en) * 2017-01-10 2020-10-21 The General Hospital Corporation T LYMPHOCYTES EXPRESSING A CHEMERICAL ANTIGENIC RECEPTOR
WO2018132427A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
KR20190141695A (ko) 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
EP4759318A2 (en) * 2017-04-14 2026-06-17 The General Hospital Corporation Chimeric antigen receptor t cells targeting the tumor microenvironment
JP2020517259A (ja) * 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
AU2018309735B2 (en) * 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
CA3078963A1 (en) 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
KR20190065234A (ko) * 2017-11-30 2019-06-11 그리폴스 다이어그노스틱 솔루션즈 인크. 면역 관문 억제제인 pd-1 및 pd-l1에 대한 항체 치료를 모니터링하기 위한 면역분석 및 조작된 단백질
CA3087476A1 (en) * 2018-01-10 2019-07-18 The General Hospital Corporation Immune cells expressing a chimeric antigen receptor
CN108314738B (zh) * 2018-01-29 2020-09-08 山东兴瑞生物科技有限公司 一种共表达细胞因子il-21的双特异性嵌合抗原受体、质粒、cik细胞及mm病应用
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
WO2019160956A1 (en) * 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
CN112041432A (zh) * 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
WO2019178342A1 (en) * 2018-03-15 2019-09-19 Fundamental Solutions Corporation Programmable immunocyte receptor complex system
US11168138B2 (en) * 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
EP3773588A4 (en) * 2018-04-09 2022-01-19 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASES
CN119656304A (zh) * 2018-04-12 2025-03-21 凯德药业股份有限公司 使用肿瘤微环境的特征的嵌合受体t细胞治疗
EP3561053A1 (en) * 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
WO2019210293A1 (en) * 2018-04-27 2019-10-31 Baylor College Of Medicine Car t cells with one or more interleukins
WO2019210207A2 (en) * 2018-04-27 2019-10-31 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis
CN110468105B (zh) * 2018-05-09 2024-03-22 恺兴生命科技(上海)有限公司 表达il-18r结合蛋白的免疫效应细胞
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
CA3103610A1 (en) * 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
CN112368021B (zh) 2018-06-14 2025-02-21 2赛文缇生物公司 Cd79a嵌合抗原受体
WO2019246593A2 (en) * 2018-06-22 2019-12-26 Fred Hutchinson Cancer Research Center Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders
WO2020009868A1 (en) 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
CN108864307A (zh) * 2018-07-23 2018-11-23 北京多赢时代科技有限公司 信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用
US20210079111A1 (en) * 2018-08-04 2021-03-18 AbCyte Therapeutics Inc. Cd19-cd20 bispecific and dual passway car-t and methods for use thereof
CN110862967A (zh) * 2018-08-27 2020-03-06 天津天锐生物科技有限公司 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
EA202190624A1 (ru) * 2018-08-31 2021-06-09 Нойл-Иммьюн Байотек, Инк. Car-экспрессирующие т-клетки и car-экспрессирующий вектор
CA3111384A1 (en) * 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
WO2020061048A1 (en) * 2018-09-17 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
WO2020061796A1 (en) * 2018-09-26 2020-04-02 Hrain Biotechnology Co., Ltd. Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20210338729A1 (en) * 2018-10-12 2021-11-04 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
CA3116138A1 (en) * 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
CN119569895A (zh) * 2018-11-01 2025-03-07 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
US12473345B2 (en) 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
WO2020113054A1 (en) 2018-11-30 2020-06-04 Mustang Bio, Inc. Methods of treatment using decitabine and a cd123-targeted therapy
KR20250116790A (ko) * 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
WO2020124021A1 (en) * 2018-12-13 2020-06-18 The General Hospital Corporation Chimeric antigen receptors targeting cd79b and cd19
IL284294B1 (en) 2018-12-24 2026-06-01 Haidong Huang Human 2IG-B7-H3 protein encoding gene, promoter vector, host cell composed thereof, pharmaceutical composition and use thereof
EP3908613A4 (en) * 2019-01-07 2022-10-19 Celluris Participações Ltda. BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA
EP3917313A4 (en) * 2019-02-01 2023-02-08 Actinium Pharmaceuticals, Inc. MOLECULES AND THEIR DERIVATIVES AGAINST CD45
KR20210137085A (ko) * 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2020197319A1 (ko) * 2019-03-28 2020-10-01 한국생명공학연구원 면역세포의 제조방법 및 그의 용도
CA3136618A1 (en) * 2019-04-10 2020-10-15 Elevatebio Technologies, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
CN110055281B (zh) * 2019-04-25 2020-09-01 山东大学第二医院 一种用于制备car-t的慢病毒载体及其构建方法和应用
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
CA3138633A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CA3136737A1 (en) * 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
EP3747904A1 (en) * 2019-06-03 2020-12-09 Universität Regensburg Cd25-specific chimeric antigen receptors and their uses
AU2020286471B2 (en) * 2019-06-07 2025-07-31 The Trustees Of The University Of Pennsylvania Dual CAR expressing T cells individually linked to CD28 and 4-1BB
MX2021015495A (es) * 2019-06-14 2022-04-18 2Seventy Bio Inc Composiciones y métodos para tratar cáncer.
WO2020263484A1 (en) * 2019-06-28 2020-12-30 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
CN112204135B (zh) * 2019-07-06 2026-03-06 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
EP3997129B1 (en) * 2019-07-11 2025-11-26 Valkyr, Inc. System and methods relating to chimeric autoantibody receptors
AU2020315213A1 (en) * 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells
CN110452294B (zh) * 2019-08-06 2020-08-07 复旦大学 五种铰链区及其嵌合抗原受体和免疫细胞
WO2021041936A1 (en) * 2019-08-28 2021-03-04 Montefiore Medical Center Cd25 chimeric antigen receptors and uses thereof
WO2021057906A1 (zh) * 2019-09-25 2021-04-01 科济生物医药（上海）有限公司 表达il-15的免疫效应细胞
WO2021064718A1 (en) * 2019-10-01 2021-04-08 Case Western Reserve University Targeting b cell activating factor receptor (baff-r) using ligand-based chimeric antigen receptor (car)-t cells
CA3153441A1 (en) * 2019-10-01 2021-04-08 Reshmi Parameswaran Targeting b cell activating factor receptor (baff-r) using ligand-based chimeric antigen receptor (car)-t cells
AU2020361683A1 (en) * 2019-10-11 2022-05-19 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
TWI717880B (zh) * 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
AU2020382219A1 (en) 2019-11-13 2022-05-12 Crispr Therapeutics Ag Manufacturing process for making T cells expressing chimeric antigen receptors
CN110760007B (zh) * 2019-11-21 2022-08-26 博生吉医药科技(苏州)有限公司 Cd7-car-t细胞及其制备和应用
US20230272035A1 (en) * 2019-12-05 2023-08-31 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
IL295878A (en) * 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
US20230174653A1 (en) * 2020-04-06 2023-06-08 St. Jude Children's Research Hospital, Inc. B7-h3 chimeric antigen receptors
CN111411085A (zh) * 2020-04-10 2020-07-14 格源致善(上海)生物科技有限公司 一种嵌合抗原受体t细胞及其应用
CN113527507A (zh) * 2020-04-16 2021-10-22 上海赛比曼生物科技有限公司 靶向cd22的嵌合抗原受体及其制法和应用
CN115777017A (zh) * 2020-05-06 2023-03-10 亘喜生物科技（上海）有限公司 用于t细胞工程改造的组合物及方法
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
WO2022040577A1 (en) * 2020-08-20 2022-02-24 City Of Hope Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells
AU2021334950A1 (en) * 2020-08-24 2023-03-02 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (CAR)-expressing cells recognizing CEA
CN116568812A (zh) * 2020-09-08 2023-08-08 亘喜生物科技（上海）有限公司 用于t细胞工程化的组合物和方法
WO2022061837A1 (en) * 2020-09-27 2022-03-31 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Fibronectin extra domain b (edb) -specific car-t for cancer
CN116783283A (zh) * 2020-11-13 2023-09-19 Gpb科学有限公司 产生具有增加的核酸摄取的细胞群体的方法
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN116981685A (zh) * 2020-12-03 2023-10-31 世纪治疗股份有限公司 基因工程化细胞及其用途
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CN115786271B (zh) * 2021-01-12 2025-07-22 上海雅科生物科技有限公司 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用
CN112778427B (zh) * 2021-01-29 2022-03-15 武汉思安医疗技术有限公司 双特异性cs1-bcma car-t细胞及其应用
US20220267423A1 (en) * 2021-02-22 2022-08-25 IgGenix, Inc. Ige antibodies cross-reactive to allergens and tumor antigens
CN112698037B (zh) * 2021-03-25 2021-06-25 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
WO2022234976A1 (ko) * 2021-05-04 2022-11-10 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR102671411B1 (ko) * 2021-05-11 2024-06-04 진화섭 Baff 세포외 도메인을 포함하는 키메릭 항원 수용체 및 이의 용도
CN115340610A (zh) * 2021-05-12 2022-11-15 珠海市丽珠单抗生物技术有限公司 双特异性car t细胞及其应用
CN113402619B (zh) * 2021-06-30 2022-03-22 徐州医科大学 一种靶向B7H3共表达IL-21的全人源嵌合抗原受体、iNKT细胞及其用途
CN113549158B (zh) * 2021-07-19 2022-10-21 广州百暨基因科技有限公司 包含突变型il15以及嵌合抗原受体的融合蛋白
US20230060292A1 (en) * 2021-07-26 2023-03-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
JP2024531910A (ja) * 2021-08-04 2024-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法
US20250222102A1 (en) * 2021-08-24 2025-07-10 City Of Hope Nk cells expressing il-15 and checkpoint inhibitors for the treatment of cancer
KR20230032557A (ko) 2021-08-31 2023-03-07 주식회사 이뮤노로지컬디자이닝랩 Baff 세포외 도메인을 포함하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
AU2022347132A1 (en) * 2021-09-16 2024-05-02 Gt Biopharma, Inc. B7-h3 targeting fusion proteins and methods of use thereof
EP4433512A4 (en) * 2021-11-19 2025-12-31 Univ Pennsylvania Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy
US20230210900A1 (en) * 2022-01-04 2023-07-06 Kyverna Therapeutics, Inc. Methods for treating autoimmune diseases
CN116606378A (zh) * 2022-02-08 2023-08-18 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向cd52的嵌合抗原受体及其应用
EP4272754A1 (en) 2022-05-04 2023-11-08 Universitätsklinikum Hamburg-Eppendorf Method for producing cells expressing a chimeric antigen receptor (car)
US20250295773A1 (en) * 2022-05-10 2025-09-25 Miltenyi Biotec B.V. & Co. KG Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
WO2024026455A2 (en) * 2022-07-29 2024-02-01 Shoreline Biosciences, Inc. Methods and compositions for generating chimeric antigen receptor-monocytes/macrophages
EP4487868A1 (en) 2023-07-06 2025-01-08 Universitätsklinikum Hamburg-Eppendorf Modified nk cell expressing a chimeric antigen receptor
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
WO2025072372A1 (en) * 2023-09-26 2025-04-03 The General Hospital Corporation Car-t cells expressing vegf binding proteins
CN117050195B (zh) * 2023-10-13 2023-12-19 旭和（天津）医药科技有限公司 一种靶向baffr嵌合抗原受体、car-t细胞和应用
WO2025264723A1 (en) * 2024-06-18 2025-12-26 The University Of Chicago Co-expressed chimeric antigen receptors for cancer treatment
WO2026082736A1 (en) * 2024-10-14 2026-04-23 Cimeio Therapeutics Ag Chimeric antigen receptor (car) that targets receptor-type tyrosine phosphatase c (cd45) and its use to related applications

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147865A1 (en) 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
JP2015513394A (ja) 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
WO2015120180A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
US20150307623A1 (en) 2012-12-20 2015-10-29 Anthrogenesis Corporation Chimeric antigen receptors
WO2015168613A2 (en) 2014-05-02 2015-11-05 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2016073755A2 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
JP2018518974A (ja) 2015-06-25 2018-07-19 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20080254027A1 (en) 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
JP4596916B2 (ja) 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
US20050277587A1 (en) 2004-06-10 2005-12-15 Academia Sinica CD7 as biomarker and therapeutic target for psoriasis
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2007120368A2 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
ES2437315T3 (es) 2006-06-12 2014-01-10 Janssen Biotech, Inc. Método para la detección de actividad IL-16 y modulación de actividad IL-16 en base a niveles RANTES proxy
WO2008140477A2 (en) 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
CA2735456C (en) * 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CA2739608A1 (en) * 2008-10-07 2010-04-15 The Regents Of The University Of California Recombinant nell protein production
EP2389443B1 (en) 2009-01-23 2018-11-14 Roger Williams Hospital Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
BRPI1013927A2 (pt) 2009-05-13 2016-04-05 Genzyme Corp métodos e composições para o tratamento de lúpus
WO2010132697A2 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
EP2325322A1 (en) 2009-11-23 2011-05-25 4-Antibody AG Retroviral vector particles and methods for their generation and use
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP5897035B2 (ja) 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド，ボルチモア 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法
WO2012154344A1 (en) 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
KR102366029B1 (ko) * 2011-09-30 2022-02-23 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
SG11201507026WA (en) * 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
ES2769574T3 (es) * 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
SI2997141T1 (sl) * 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
JP6136650B2 (ja) * 2013-06-28 2017-05-31 ブラザー工業株式会社 カートリッジ
CA2920539C (en) * 2013-08-08 2024-01-02 Cytune Pharma Combined pharmaceutical composition
US20160250258A1 (en) 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
EP3858379A1 (en) 2013-11-21 2021-08-04 Autolus Limited Cell
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
JP6665102B2 (ja) * 2014-02-21 2020-03-13 セレクティスＣｅｌｌｅｃｔｉｓ 制御性ｔ細胞をインサイチューで阻害するための方法
SG10201808811QA (en) * 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
JP6682509B2 (ja) 2014-05-14 2020-04-15 カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3712171A1 (en) * 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
GB201518817D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Cell
JP6976960B2 (ja) * 2015-11-27 2021-12-08 カーサリクス プロプライエタリー リミテッド 遺伝子改変された細胞およびその使用
SG11201807489PA (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
JP7467117B2 (ja) * 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147865A1 (en) 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
JP2015513394A (ja) 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
US20150307623A1 (en) 2012-12-20 2015-10-29 Anthrogenesis Corporation Chimeric antigen receptors
WO2015120180A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
WO2015168613A2 (en) 2014-05-02 2015-11-05 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2016073755A2 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
JP2018518974A (ja) 2015-06-25 2018-07-19 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
JP6961497B2 (ja) 2015-06-25 2021-11-05 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法

Also Published As

Publication number Publication date
US20180162939A1 (en) 2018-06-14
EP3474867A4 (en) 2020-05-20
US20200024342A9 (en) 2020-01-23
US11820819B2 (en) 2023-11-21
US20200283534A1 (en) 2020-09-10
JP2019522973A (ja) 2019-08-22
EP3474867A1 (en) 2019-05-01
CA3029197A1 (en) 2017-12-28
EP4353750A3 (en) 2024-07-24
US20240141041A1 (en) 2024-05-02
CN109562126A (zh) 2019-04-02
EP4353750A2 (en) 2024-04-17
US20230340113A1 (en) 2023-10-26
WO2017222593A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
US20230340113A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
JP7502515B2 (ja) キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US12275787B2 (en) Chimeric antigen receptors (CARs), compositions and methods thereof
US20240059754A1 (en) Chimeric antigen receptors and enhancement of anti-tumor activity
JP7237449B2 (ja) 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US20210269501A1 (en) Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220727

R150 Certificate of patent or registration of utility model

Ref document number: 7114490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250